NCT04791319

A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis

A Phase 2b, Multicenter, Randomized, Placebo- and Active-comparator-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Participants With Moderate to Severe Atopic Dermatitis

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 199 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of bermekimab in participants with moderate to severe atopic dermatitis (AD).

Conditions

• Dermatitis, Atopic

Interventions

Type	Name	Description
DRUG	Placebo	Placebo will be administered subcutaneously.
DRUG	Bermekimab	Bermekimab will be administered subcutaneously.
DRUG	Dupilumab	Dupilumab will be administered subcutaneously.

Timeline

• Start date: 2021-05-03
• Primary completion: 2022-02-02
• Completion: 2022-03-31
• First posted: 2021-03-10
• Last updated: 2023-03-01
• Results posted: 2023-03-01

Locations

42 sites across 5 countries: United States, Canada, Germany, Japan, Poland

Regulatory

• FDA-regulated drug study